Canada Life’s Quince Therapeutics QNCX Stock Holding History

Canada Life’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	-$7K	–	2459
2022 Q1	$7K	Hold	5	–	–	﹤0.01%	2456
2021 Q4	$13K	Hold	5	–	–	﹤0.01%	2426
2021 Q3	$94K	Hold	5	–	–	﹤0.01%	2062
2021 Q2	$54K	Hold	5	–	–	﹤0.01%	2248
2021 Q1	$37K	Hold	5	–	–	﹤0.01%	2390
2020 Q4	$28K	Hold	5	–	–	﹤0.01%	2478
2020 Q3	$51K	Hold	5	–	–	﹤0.01%	2175
2020 Q2	$47K	Buy	+5	New	+$45.8K	﹤0.01%	2235

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Canada Life's QNCX Position: Q2 2022 in Review

Canada Life sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 5 shares — an estimated $7K sold.

Canada Life first reported a position in QNCX in Q2 2020 and held it in 8 quarters. The position peaked at $94K in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

Canada Life reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
Canada Life sold 5 Quince Therapeutics shares in Q2 2022, an estimated $7K.
Canada Life first reported a position in Quince Therapeutics in Q2 2020 and held it in 8 quarters.
Canada Life's Quince Therapeutics position peaked at $94K in Q3 2021.
66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Canada Life's 13F filing for Q2 2022, filed 9 Aug 2022.